Details of the Drug

General Information of Drug (ID: DMIHRNA)

Drug Name

Tolazamide

Synonyms

Diabewas; Norglycin; Tolamide; Tolanase; Tolazamida; Tolazamidum; Tolazolamide; Tolinase; Pharmacia Brand of Tolazamide; T 2408; U 17835; Tolazamida [INN-Spanish]; Tolazamidum [INN-Latin]; Tolinase (TN); U-17835; Tolazamide (JP15/USP/INN); Tolazamide [USAN:INN:BAN:JAN]; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; 59866P

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1], [2]

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

311.4

Topological Polar Surface Area (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 53.62778 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.278 mg/mL [3]

Chemical Identifiers

Formula: C14H21N3O3S
IUPAC Name: 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea
Canonical SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
InChI: InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
InChIKey: OUDSBRTVNLOZBN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5503
ChEBI ID: CHEBI:9613
CAS Number: 1156-19-0
DrugBank ID: DB00839
TTD ID: D09FJB
INTEDE ID: DR1611
ACDINA ID: D00684

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inward rectifier potassium channel Kir1.2 (KCNJ10)	TTG140O	KCJ10_HUMAN	Blocker	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tolazamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Tolazamide due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[24]
Tromethamine	DMOBLGK	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tolazamide caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[25]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Oxymetholone.	Aplastic anaemia [3A70]	[26]
Clarithromycin	DM4M1SG	Moderate	Increased plasma concentration of Tolazamide and Clarithromycin due to competitive binding of plasma proteins.	Bacterial infection [1A00-1C4Z]	[27]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[26]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Tolazamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[29]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[29]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Ketoprofen.	Chronic pain [MG30]	[29]
Ardeparin	DMYRX8B	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Ardeparin.	Coronary thrombosis [BA43]	[29]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Tolazamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[30]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Tolazamide caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[31]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Sertraline.	Depression [6A70-6A7Z]	[29]
Vilazodone	DM4LECQ	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Vilazodone.	Depression [6A70-6A7Z]	[29]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Selegiline.	Depression [6A70-6A7Z]	[29]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Vortioxetine.	Depression [6A70-6A7Z]	[29]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Isocarboxazid.	Depression [6A70-6A7Z]	[29]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Escitalopram.	Depression [6A70-6A7Z]	[29]
SODIUM CITRATE	DMHPD2Y	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tolazamide caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[25]
Miconazole	DMPMYE8	Major	Decreased metabolism of Tolazamide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[29]
Sulfinpyrazone	DMEV954	Moderate	Decreased renal excretion of Tolazamide caused by Sulfinpyrazone.	Gout [FA25]	[32]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Tolazamide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Tolazamide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[34]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Tolazamide caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Gemfibrozil	DMD8Q3J	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[29]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[29]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Captopril.	Hypertension [BA00-BA04]	[29]
Methyldopa	DM5I621	Minor	Decreased metabolism of Tolazamide caused by Methyldopa.	Hypertension [BA00-BA04]	[36]
Quinapril	DMR8H31	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Quinapril.	Hypertension [BA00-BA04]	[29]
Sodium acetate anhydrous	DMH21E0	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Tolazamide caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[25]
Probenecid	DMMFWOJ	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[29]
Balsalazide	DMO091F	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Balsalazide.	Indeterminate colitis [DD72]	[29]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[26]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tolazamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[37]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[29]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Sulphadoxine.	Malaria [1F40-1F45]	[26]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tolazamide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[29]
Aspirin	DM672AH	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Aspirin.	Pain [MG30-MG3Z]	[26]
Diflunisal	DM7EN8I	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Diflunisal.	Pain [MG30-MG3Z]	[29]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Ibuprofen.	Pain [MG30-MG3Z]	[29]
Safinamide	DM0YWJC	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Safinamide.	Parkinsonism [8A00]	[29]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Rasagiline.	Parkinsonism [8A00]	[29]
Ranitidine	DM0GUSX	Moderate	Decreased absorption of Tolazamide due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[38]
Famotidine	DMRL3AB	Moderate	Decreased absorption of Tolazamide due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[38]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[26]
Bromfenac	DMKB79O	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Bromfenac.	Postoperative inflammation [1A00-CA43]	[26]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Salsalate.	Rheumatoid arthritis [FA20]	[29]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Oxaprozin.	Rheumatoid arthritis [FA20]	[29]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Tolazamide caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[39]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[26]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[29]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[29]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[29]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Tolazamide and Olsalazine.	Ulcerative colitis [DD71]	[29]
-----------


⏷ Show the Full List of 55 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tolazamide 250 mg tablet	250 mg	Oral Tablet	Oral
Tolazamide 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6847).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018894.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4.
7	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
8	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
9	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
10	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
11	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
12	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
13	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
14	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
15	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
16	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
17	Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6.
18	Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
19	Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8.
20	Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113.
21	Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51.
22	Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
23	Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
24	Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
25	Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
26	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
27	Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
28	Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
29	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
30	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
31	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32	Mahfouz M, Abdel-Maguid R, El-Dakhakhny M "Potentiation of the hypoglycaemic action of tolbutamide by different drugs." Arzneimittelforschung 20 (1970): 120-2. [PMID: 5467602]
33	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
34	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
36	Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
37	Cerner Multum, Inc. "Australian Product Information.".
38	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
39	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.